Peptide patent landscapes shape the competitive dynamics of the biopharmaceutical industry. Patent expirations create biosimilar opportunities, while new formulation and delivery patents extend market exclusivity. This reference covers key patent events for major therapeutic peptides.
| Peptide | Originator | Patent Expiry (US) | Patent Expiry (EU) | Biosimilar Status |
|---|
| Insulin Glargine (Lantus) | Sanofi | 2015 | 2015 | Multiple biosimilars |
| Insulin Lispro (Humalog) | Eli Lilly | 2013 | 2013 | Biosimilars available |
| Insulin Aspart (NovoLog) | Novo Nordisk | 2013 | 2013 | Biosimilars available |
| Insulin Glulisine (Apidra) | Sanofi | 2015 | 2015 | Limited biosimilars |
| Liraglutide (Victoza) | Novo Nordisk | 2023 | 2023 | Under development |
| Exenatide (Byetta) | AstraZeneca | 2010 | 2010 | Generic available |
| Octreotide (Sandostatin) | Novartis | 2014 | 2014 | Biosimilars available |
| Goserelin (Zoladex) | AstraZeneca | 2015 | 2015 | Generic available |
| Leuprolide (Lupron) | AbbVie | 2015 | 2015 | Generic available |
| Desmopressin (DDAVP) | Ferring | Various | Various | Generics available |
| Peptide | Originator | Expected Expiry | Significance |
|---|
| Semaglutide (Ozempic/Wegovy) | Novo Nordisk | 2031–2032 | Largest GLP-1 market |
| Tirzepatide (Mounjaro/Zepbound) | Eli Lilly | 2033–2036 | Dual agonist leader |
| Dulaglutide (Trulicity) | Eli Lilly | 2027–2028 | Weekly GLP-1 |
| Insulin Degludec (Tresiba) | Novo Nordisk | 2030–2031 | Ultra-long basal |
| Liraglutide (Saxenda) | Novo Nordisk | 2023–2025 | Obesity indication |
| Semaglutide oral (Rybelsus) | Novo Nordisk | 2031–2032 | Oral GLP-1 |
Formulation patents can extend effective market exclusivity beyond composition-of-matter patents:
| Strategy | Example | Expiry Extension |
|---|
| Sustained release formulations | Ozempic (autoinjector) | +5–8 years |
| Oral formulations (SNAC) | Rybelsus | +8–10 years |
| Depot formulations | Exenatide ER (Bydureon) | +5–8 years |
| Device patents | Pen needle systems | +3–5 years |
| Combination products | Fixed-ratio combinations | +5–8 years |
| Indication | Peptide | Patent Status |
|---|
| Obesity | Semaglutide (Wegovy) | Valid until 2031–2032 |
| MASH/NASH | Semaglutide | Under investigation |
| Heart failure | Semaglutide | SELECT trial data |
| Sleep apnea | Tirzepatide | Under investigation |
| CKD | Semaglutide | FLOW trial data |
| Process | Patent Holder | Significance |
|---|
| Solid-phase peptide synthesis (SPPS) | Various (expired) | Generic SPPS available |
| Continuous flow SPPS | Various | Active patenting |
| Green chemistry processes | Various | Sustainability advantage |
| Purification methods | Various | Cost reduction |
| Reference Product | Biosimilar | Manufacturer | Status |
|---|
| Insulin Glargine (Lantus) | Basaglar | Eli Lilly | Approved |
| Insulin Glargine (Lantus) | Admelog | Sanofi | Approved |
| Insulin Lispro (Humalog) | Admelog | Sanofi | Approved |
| Insulin Aspart (NovoLog) | Fiasp | Novo Nordisk | Approved |
| Octreotide (Sandostatin) | Octreotide acetate | Various | Approved |
| Reference Product | Biosimilar Developers | Stage |
|---|
| Liraglutide (Victoza) | Multiple | Phase III |
| Semaglutide (Ozempic) | Multiple | Early development |
| Dulaglutide (Trulicity) | Multiple | Early development |
| Insulin Degludec (Tresiba) | Multiple | Phase II/III |
| Case | Peptide | Outcome | Impact |
|---|
| Sanofi v. Eli Lilly | Insulin Glargine | Biosimilar entry | Price reduction |
| Novo Nordisk v. Various | Semaglutide | Multiple patents upheld | Delayed biosimilars |
| Eli Lilly v. AstraZeneca | Exenatide | Generic entry | Market shift |
| Teva v. Sanofi | Liraglutide | Settlement | Delayed biosimilar |
| Category | Patent Status | Biosimilar Opportunity |
|---|
| Rapid-acting | Expired | High |
| Long-acting (glargine) | Expired | High |
| Long-acting (degludec) | Active (2030+) | Moderate |
| Ultra-long (degludec) | Active | Low (near-expiry) |
| Concentrated (U-300) | Active | Low |
| Category | Patent Status | Biosimilar Opportunity |
|---|
| Exenatide | Expired | High |
| Liraglutide | Near-expiry | Moderate |
| Dulaglutide | Near-expiry (2027) | Moderate |
| Semaglutide | Active (2031+) | Low |
| Tirzepatide | Active (2033+) | Low |
| Category | Patent Status | Biosimilar Opportunity |
|---|
| Sermorelin | Expired | High |
| Tesamorelin | Active | Low |
| CJC-1295 | Expired (research) | Available for research |
| Ipamorelin | Expired (research) | Available for research |
| Peptide | Original Indication | Opportunity |
|---|
| BPC-157 | Research (no approved indication) | Clinical development |
| TB-500 | Research (veterinary) | Clinical development |
| GHK-Cu | Cosmetic (topical) | Therapeutic development |
| Melanotan II | Research (cosmetic) | Clinical development |
| PT-141 | Research (sexual health) | FDA-approved (bremelanotide) |
| Technology | Patent Status | Application |
|---|
| Oral peptide delivery (SNAC-like) | Various active | Oral GLP-1 alternatives |
| Implantable devices | Active | Ultra-long-acting delivery |
| Microneedle patches | Active | Painless SC delivery |
| Intranasal devices | Various | CNS-targeted peptides |
| Peptide | Pre-Expiry Price | Post-Expiry Price | Reduction |
|---|
| Insulin Glargine | $300/vial | $100–150/vial | 50–67% |
| Insulin Lispro | $300/vial | $100–150/vial | 50–67% |
| Octreotide | $500/month | $200–300/month | 40–60% |
| Leuprolide | $400/month | $100–200/month | 50–75% |
| Peptide | 2024 Revenue | Patent Cliff | Revenue at Risk |
|---|
| Semaglutide | ~$25B | 2031–2032 | ~$25B |
| Tirzepatide | ~$10B | 2033–2036 | ~$10B |
| Dulaglutide | ~$5B | 2027–2028 | ~$5B |
| Insulin Degludec | ~$3B | 2030–2031 | ~$3B |
- Composition-of-matter patents (20 years from filing) protect the molecule itself
- Formulation patents can extend effective exclusivity by 5–10 years
- Method-of-use patents protect specific indications but not the molecule
- Device patents protect delivery systems, not the drug
- Biosimilar pathways (BPCIA in US, similar in EU) enable competition post-exclusivity
- Patent thickets (multiple overlapping patents) can delay biosimilar entry
- Paragraph IV certifications enable generic challenge of Orange Book patents
